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Abstract
Cardiovascular Magnetic Resonance (CMR) is a not invasive diagnostic imaging tool for the detection of the most common heart diseases. 
It creates images from atomic nuclei with uneven spin using radiowaves in the presence of a magnetic field. For clinical purposes, magnetic 
resonance (MR) is performed using hydrogen-1, which is abundant in water and fat. Radiofrequency waves excite the area of interest to 
create tissue magnetization that decays (relaxation) and after a short period is induced to release energy as a radio signal. These echoes 
are converted with Fourier transformation into images of spatially resolved radio signals. Relaxation is quantified in spatially orthogonal 
directions as T1 and T2, which allows tissue characterization to serve as a powerful clinical tool. Recently CMR has become the gold standard 
for evaluating myocardial function, volumes, and scarring. It is an indispensable tool in the evaluation of congenital heart disease, heart 
failure, cardiac masses, pericardial disease, and coronary artery disease. Cardiovascular magnetic resonance imaging is unique   in   its 
comprehensive   tissue   characterization,   including   assessment   of myocardial oedema, myocardial siderosis, myocardial perfusion, and 
diffuse myocardial fibrosis. This review is focused on advantages of the detection of suspected cardiomyopathies, in particular in the case 
of the dilatative cardiomyopathy, the hypertrophic cardiomyopathy and the right ventricular arrhythmia cardiomyopathy that have been 
examined in this tractation
Cardiovascular Magnetic Resonance, Cardiac Imaging, Heart Diseases, Cardiomyopathies, Hearth FailureKeywords:
Introduction
In a few years magnetic resonance imaging has taken a crucial role in 
the study of cardiomyopathy both on an ischemic and non-ischemic 
basis, and in the evaluation of patients with heart failure1-5. This 
technique, known as Cardiovascular Magnetic Resonance, is unique 
to the diagnosis and assessment of cardiomyopathies. Consequently, 
in cardiomyopathy magnetic resonance is today a precise and reliable 
instrument for diagnosis and for prognostic stratification when it 
comes to a structural damage6. 
What  can be diagnosed  by using the cardiac magnetic  resonance 
imaging?
Due to the development of specific image sequences, the use of 
a medical contrast medium and the implementation of innovative 
solutions such as hardware and image reconstruction, it is now 
possible to check heart anatomy and function. In particular, physicians 
can investigate heart perfusion, oedema, fibrosis, haemorrhage, and 
iron content of the cardiac muscle2.
The classic Cardiovascular Magnetic Resonance imaging (CMR) – 
sometimes known as cardiac MRI scanner prototype – provides a 
magnetic range of 1.5-3T, a dedicated coil for multi-channel heart 
study, and specific software that includes sequences for heart study, 
as well as appropriate calculation algorithms5. Today all scanners can 
be used for heart and vase studies as long as hardware and software 
for electrocardiogram signalling are available. These are necessary to 
synchronize the data acquisition with the movements of the heart, and 
the sequences suitable for the evaluation of both morpho-functional 
and variations of the signals induced by the blood flow and contrast 
media18. The standard exam begins with dark blood sequences for 
classical anatomical evaluation,  followed by several light blood 
sequences for the volume  and kinetic analysis of cardiac chambers 
and valve devices. The use of a contrast medium – the most widely 
used are gadolinium chelates – influences the magnetic properties of 
the myocardium.  Analysis of the signal intensity variations over time 
at the first passage allows evaluation of any perfusion heterogeneity, 
while late-on analysis allows verification of the presence of extra 
vascular accumulation, usually associated with fibrosis2-26.
The CMR can also highlight areas of delayed enhancement in 
cardiomyopathy, and it is now clear that this phenomenon  is linked  to 
the  particular  tissue  and cellular distribution of gadolinium chelate7. 
The delayed enhancement phenomenon occurs when, a few minutes 
after the administration of the ferromagnetic contrast medium, the 
signal increases over the surrounding myocardium because of the 
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changes in magnetization induced in the tissue under examination. 
In the case of acute infarction, gadolinium penetrates the cells and 
produces the typical signal increase at the delayed enhancement after 
a few minutes of the lesion. In the later phase, known as the repair 
phase, gadolinium occupies the extracellular space left free from 
the cells. Thus, the presence of delayed enhancement areas simply 
reflects the repairing fibrosis. A complete study of the heart anatomy, 
function, rest and stress perfusion, as well as delayed enhancement, 
can be completed in 40-50 min. The absence of ionizing radiation and 
the good quantity of information that can be obtained in one exam, 
make the CMR a technique of great clinical interest2-26. 
Cardiomyopathies
Cardiomyopathies (CMPs) are very different myocardial diseases. 
According to the classification of the American Heart Association in 
2006, they are distinguished by primitive forms and secondary forms8. 
Among the primitive forms are those acquired, genetically transmitted, 
and a mixture of the two. The European Cardiology Society in 2008 
differentiated cardiomyopathies on both morphological and functional 
aspects9.
The CMR can characterize the clear majority of CMPs of clinical interest 
from the morpho-functional point of view. No single diagnostic tool 
has the versatility, robustness, simplicity, immediacy of information, 
accuracy, and clinical applicability of CMR.
In a recent CMR consent document, the use of CMPs is considered 
appropriate to both identify an aetiology of a cardiopathy due to an 
unknown cause associated with heart failure, and to better assess 
patients with suspected but not characterized cardiopathies10.  For 
example,  the ischemic  aetiology or related coronary atherosclerosis 
are generally easy to detect due to the presence of one or more 
lesions of the left ventricle that characterize it11-13. Today CMR is the 
only non-invasive method  that  can  detect  a  precocious  infarction 
with  high  accuracy.  Outside  the ischemic aetiology, CMR can identify 
the aetiology of a cardiopathy in the presence of a left ventricular 
dysfunction of uncertain origin12-15.
Thanks to the combination of morpho-functional aspects and to the 
presence of specific delayed enhancement pattern (observed after 
the administration of the contrast medium),  the CMR can detect 
with  a high degree of accuracy:  primitive  dilated cardiomyopathy, 
hypertrophic cardiomyopathy, amyloidosis and other forms of 
restriction, right ventricular cardiomyopathy, and other diseases that 
may result in non- ischemic myocardial injury.
Over the years CMR has not only played a major role in the diagnosis 
of cardiopathy but has also shown significant prognostic ability6. The 
prognostic role of CMR is demonstrated  by its ability to identify the 
presence and to measure the extent of myocardial scarring. CMR can 
work with recognized markers and factors usually detected with the 
other relevant diagnostic methods14.
The presence and magnitude of myocardial fibrosis is particularly 
relevant, not only because it is traditionally evaluated, but because 
it makes up a large part of the clinical research. New sequences 
and specific technical approaches for the collection of quantitative 
and accurate measurements of pathological quantities of collagen, 
allows CMR to be used for both diagnosis and prognosis of in many 
pathological conditions including cardiomyopathies16. 
In conclusion, for all the above-mentioned features, it can be stated 
that CMR can be considered a definitive examination technique 
to identify both aetiology and prognosis in the presence of many 
established or suspected cardiomyopathies.
 
Figure 1: Cardiovascular Magnetic Resonance  of Acute Myocarditis
Panel A: T2-weighted image of LV myocardial edema  showing global bright signal intensity (ratio 2.2) of the left ventricle relative to the 
myocardium. 
Panel B: Early enhancement (T1-weighted spin echo) before (left) and after (right) Gd administration; enhancement
ratio 5.4.
Panel C: Arrows indicating late enhancement (T1-weighted gradient echo sequence with myocardial nulling) 10 minutes after Gd. Gd indi-
cates gadolinium; and LV, left ventricular. Hundley W.G., Bluemke D.A., Finn J.P. et al. ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus 
Document on Cardiovascular Magnetic Resonance 2010, 55, 2614-2662
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The dilatative cardiomyopathy
In the primitive dilative form, CMR provides for the evaluation of 
volumetric, mass and ventricular kinetic parameters that are not 
affected by geometric changes in the heart. These parameters  can be 
measured  accurately,  and this allows surgeons to evaluate whether 
an implanted device is required. In addition, it provides accurate 
prognostic elements and highlights opportunities for unplanned 
prognostic stratification12.
The most interesting element of CMR imaging is the ability to exclude 
the ischemic aetiology of a cardiomyopathy with a high degree of ac-
curacy. This is usually the result of one or more myocardial necrosis 
that causes scars that can be identified using the delayed enhance-
ment technique. In the so-called “primitive” forms, it is possible to 
document predominantly intra-myocardial scars. However, some-
times scars appear 
“ischemic”12-15 and so the absence of subendocardial or transmural 
delayed enhancement areas can be used to virtually exclude the 
presence of ischemic heart disease17,18.
CMR diagnostic targets in dilatative forms are: progressive left 
ventricular dilatation, changes in systolic function, and the presence of 
myocardial  fibrosis. Myocardial fibrosis is correlated to the presence 
of malignant ventricular arrhythmias and, consequently, there is a 
probability of effective discharge of implantable defibrillators used in 
primary prevention19.
For several years, CMR has been shown to play a major role in 
recognizing signs of inflammation and myocardial involvement in 
myocarditis20. It has also shown that it can highlight, locate, and quantify 
both oedema and hyperaemia as well as the fibrosis that occurs in this 
condition. Today, it is also possible to diagnose myocarditis in 80% of 
cases by using specific sequences with CMR alone21.
Pathology expression is determined by oedema, hyperaemia and 
cellularity that participate in inflammation, which is manifested by 
the typical but not exclusive side of the lateral wall, the predominant 
subepicardic expression, and often the complete transitionality of 
delayed enhancement. Such features may, in selected cases, allow 
diagnosis, while avoiding invasive manoeuvres such as endomyocardial 
biopsy21,22.
The hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is generally easily recognized 
by echocardiography and does not pose significant problems 
with pathophysiological assessment. By using the standard 
echocardiographic   examination,   the   presence   and   magnitude 
of   an obstruction, involvement of the left atrium, or any non-synergic 
areas can be easily highlighted. CMR over the years has demonstrated 
superior ability to recognize hypertrophy areas also present in 
myocardial segments that are otherwise unobtrusive23,24. With the 
use of delayed enhancement for several years it has been possible to 
document the presence of scar tract areas in the left ventricle of many 
patients with hypertrophic cardiomyopathy25.
The recent American College of Cardiology Foundation (ACCF)/ 
AHA guidelines for the diagnosis and treatment of hypertrophic 
cardiomyopathy have introduced CMR for the first time among 
techniques that have a major impact both in the differential diagnosis 
of this pathology and in prognostic stratification. This gives CMR a key 
role in detecting areas of ventricular scarring26.
Finally, CMR was used in Fabry’s disease of chromosome X linked 
lysosomal disease caused by the deficiency of the alpha-galactosidase 
enzyme. In a recent register, 0.5% of patients with suspected 
hypertrophic cardiomyopathy have this nosological entity27
17
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The right ventricular arrhythmia cardiomyopathy
The first description in the literature of a diagnosis made by CMR 
was in 1987 and featured a case of right ventricular arrhythmia 
cardiomyopathy (CAVD)28. Since then, much progress has been made 
and today CMR can highlight morpho-functional alterations more 
accurately than those obtained by echocardiography.  Specifically, 
improvements have been made to the alterations of the endocardial 
profile, diastolic bulging areas, microaneurisms, and accentuated 
trabecularity. Similarly, changes in the volume  and kinetic  of the right 
ventricle  are easily detected29-31.  Today CMR  is considered the most 
reliable and accurate technique for the study of the right ventricle32. 
CMR can highlight areas of reduced systolic wall thickening and areas 
of altered regional kinetics, which may also affect the left ventricle in 
advanced cases. Along with the alterations of the regional and global 
kinetics of the right ventricle, and in the absence of known causes, 
patients with CAVD may exhibit alterations in the wall signal after 
administration of the contrast medium33. The ACC / AHA attributed the 
highest degree of appropriateness for this application, and this was 
also confirmed by a review of the diagnostic criteria of the disease by 
a special Commission of the European Cardiology Society34.
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Figure 2: Representative patient images. 
(A) Patient with asymmetric septal hypertrophy, maximum wall thickness of
20 mm, normal ejection fraction, and marked myocardial scarring (hyperenhancement shown by arrows). 
(B) Patient with greater hypertrophy (maximum wall thickness, 27 mm) but with less scarring. In both patients, there  are multiple foci of 
scar, which are predominantly mid-myocardial in location and are not present in the lateral free wall. The long- axis cines images of Patient 19 
demonstrate systolic anterior  motion of the mitral valve, systolic flow turbulence in the left ventricular outflow tract, and mitral regurgitation. 
Choudhury L., Mahrholdt  H., Wagner A., et al. Myocardial
scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy 2002, 40, 2156-64
Figure 3:  MRI in a patient with arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVD/C) Calkins H. et al. In Shenasa 
M. et al, The future of cardiac mapping: Dawn of a New Decade, in Cardiac Mapping, M Shenasa, Editor. 2013
Calkins H,et al. In Shenasa M, et al, editors.
Cardiac Mapping. 4th edition. New York: Wiley-Blackwell; 2013. p. 680;2013.
The other cardiomyopathies
Over the last few years, all major cardiomyopathies have been 
examined with CMR, which has allowed their main features to be 
described. Among these there are: non- compaction cardiomyopathy, 
heart amyloidosis, and numerous other primitive or secondary 
myocardial conditions such as sarcoidosis or hemochromatosis35,36.
Differential diagnosis of cardiomyopathies
The clinical diagnosis of non-ischemic cardiomyopathy is often 
linked to the exclusion of a diagnosis of coronary artery disease. 
Consequently, the standard exam used to exclude coronary heart 
disease is coronary angiography. This examination offers a luminous 
view of the coronary artery vessels,  allowing  the presence  of coronary 
obstructive  lesions  to be accurately highlight.  Today it is clear that 
conventional coronary artery disease is not able to accurately describe 
the presence or absence of non-obstructive coronary atherosclerosis. 
This can be more effectively described by intravascular  ultrasound  or 
coronary computerized  tomography38,39.  Thanks to the increasing use 
of coronary multilayer computerized tomography, it is now possible 
to exclude coronary heart disease in the presence of an unknown 
ventricular dysfunction in all patients40.
Conclusions
CMR is a non-invasive, polyparametric, quantitative, repeatable diag-
nostic method that is particularly useful in the diagnosis, follow up, 
and prognostic stratification of patients with cardiomyopathy. With-
in the limits of etiologic classifications, CMR can recognize most car-
diomyopathies through identification of peculiar features based on 
anatomical, functional, and structural aspects that would otherwise 
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be unavailable. In some circumstances it can be a valid alternative to 
myocardial biopsy, especially where the CMR diagnostic aspects are 
particularly specific. In many cases CMR can also detect the aetiology 
of cardiomyopathy and optimize the clinical pathways through an oth-
erwise unpredictable prognostic evaluation. Despite the crucial role of 
other diagnostic methods, primarily echocardiography,  CMR is today 
a tool that allows unprecedented level of clinical vision both on the 
diagnostic side and in the therapeutic choice. In addition, it can also 
identify the risk of patient emergencies with suspected or confirmed 
cardiomyopathy with an increased degree of accuracy.
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